Compare Stocks: INMB, WHWK, ADAG, and ORMP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.06 -14.2%	$3.33	$1.30 ▼ $4.85	$136.07M	0.54	384,289 shs	379,601 shs
INMB INmune Bio	$1.57 -4.8%	$2.12	$1.09 ▼ $2.60	$43.57M	0.89	338,050 shs	196,169 shs
ORMP Oramed Pharmaceuticals	$4.07 -2.6%	$4.65	$2.09 ▼ $5.47	$169.30M	1.29	173,963 shs	277,085 shs
WHWK Whitehawk Therapeutics	$2.89 -4.9%	$4.15	$1.97 ▼ $5.49	$164.76M	0.92	393,525 shs	273,976 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	-25.36%	-38.87%	-42.62%	+15.08%
INMB INmune Bio	0.00%	-16.93%	-27.98%	-17.37%	-18.65%
ORMP Oramed Pharmaceuticals	0.00%	-6.00%	-12.85%	+0.99%	+79.30%
WHWK Whitehawk Therapeutics	0.00%	-17.90%	-29.17%	-25.71%	+37.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.06 -14.2%	$3.33	$1.30 ▼ $4.85	$136.07M	0.54	384,289 shs	379,601 shs
INMB INmune Bio	$1.57 -4.8%	$2.12	$1.09 ▼ $2.60	$43.57M	0.89	338,050 shs	196,169 shs
ORMP Oramed Pharmaceuticals	$4.07 -2.6%	$4.65	$2.09 ▼ $5.47	$169.30M	1.29	173,963 shs	277,085 shs
WHWK Whitehawk Therapeutics	$2.89 -4.9%	$4.15	$1.97 ▼ $5.49	$164.76M	0.92	393,525 shs	273,976 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	-25.36%	-38.87%	-42.62%	+15.08%
INMB INmune Bio	0.00%	-16.93%	-27.98%	-17.37%	-18.65%
ORMP Oramed Pharmaceuticals	0.00%	-6.00%	-12.85%	+0.99%	+79.30%
WHWK Whitehawk Therapeutics	0.00%	-17.90%	-29.17%	-25.71%	+37.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.80	Moderate Buy	$8.67	320.71% Upside
INMB INmune Bio	2.50	Moderate Buy	N/A	N/A
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
WHWK Whitehawk Therapeutics	2.75	Moderate Buy	$8.33	188.35% Upside

Current Analyst Ratings Breakdown

Latest INMB, WHWK, ADAG, and ORMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	ADAG Adagene	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	WHWK Whitehawk Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$9.00
9/14/2026	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$7.00
9/10/2026	ADAG Adagene	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$9.00
9/8/2026	ORMP Oramed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C+)
9/2/2026	WHWK Whitehawk Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/19/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$9.29M	14.65	N/A	N/A	$0.75 per share	2.75
INMB INmune Bio	N/A	N/A	N/A	N/A	$0.88 per share	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	$0.09 per share	44.86	$5.02 per share	N/A
WHWK Whitehawk Therapeutics	$7.14M	23.08	N/A	N/A	$2.89 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$17.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	-$45.93M	-$0.67	N/A	N/A	N/A	N/A	-82.87%	-62.23%	10/29/2026 (Estimated)
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	0.99	N/A	N/A	N/A	-5.17%	-4.54%	11/12/2026 (Estimated)
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A

Latest INMB, WHWK, ADAG, and ORMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ORMP Oramed Pharmaceuticals	$0.43	N/A	N/A	N/A	N/A	N/A
10/29/2026	Q3 2026	INMB INmune Bio	-$0.1467	N/A	N/A	N/A	$1.88 million	N/A
8/10/2026	Q2 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.09	-$0.52	$1.84	N/A	N/A
8/6/2026	Q2 2026	INMB INmune Bio	-$0.2067	-$0.05	+$0.1567	-$0.05	$1.16 million	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	6.14%	N/A	6.07%	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	5.02	N/A
INMB INmune Bio	N/A	4.04	4.04
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98
WHWK Whitehawk Therapeutics	N/A	17.38	17.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
INMB INmune Bio	12.72%
ORMP Oramed Pharmaceuticals	12.73%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
INMB INmune Bio	21.40%
ORMP Oramed Pharmaceuticals	20.77%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	128	66.05 million	52.05 million	Not Optionable
INMB INmune Bio	21	27.75 million	21.82 million	Optionable
ORMP Oramed Pharmaceuticals	13	41.60 million	32.96 million	Optionable
WHWK Whitehawk Therapeutics	23	57.01 million	28.56 million	N/A

INMB, WHWK, ADAG, and ORMP Headlines

Recent News About These Companies

Biogen (NASDAQ:BIIB) and Whitehawk Therapeutics (NASDAQ:WHWK) Head to Head Survey

October 16 at 3:59 AM | americanbankingnews.com

Whitehawk Therapeutics (NASDAQ:WHWK) and Surrozen (NASDAQ:SRZN) Critical Comparison

October 14, 2026 | americanbankingnews.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages

October 8, 2026 | marketbeat.com

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 As A Durable ADC Target In Ovarian Cancer And Reinforces Scientific Rationale For HWK-016

October 3, 2026 | marketscreener.comM

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

October 1, 2026 | prnewswire.com

Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Whitehawk Therapeutics: PTK7 Stability Supports ADC Development In EGFR Wild-Type NSCLC

September 14, 2026 | rttnews.com

Whitehawk data support PTK7 target for HWK-007

September 14, 2026 | grafa.comG

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

September 13, 2026 | prnewswire.com

Whitehawk Therapeutics Adds Oncology Leader to Board

September 10, 2026 | tipranks.com

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

September 10, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

September 2, 2026 | prnewswire.com

What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?

August 28, 2026 | zacks.com

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

August 26, 2026 | zacks.com

Whitehawk Therapeutics Inc WHWK

August 14, 2026 | morningstar.comM

TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)

August 10, 2026 | theglobeandmail.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6, 2026 | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6, 2026 | prnewswire.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, WHWK, ADAG, and ORMP Company Descriptions

Adagene NASDAQ:ADAG

$2.06 -0.34 (-14.17%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$2.05 -0.01 (-0.49%)

As of 10/16/2026 07:30 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

INmune Bio NASDAQ:INMB

$1.57 -0.08 (-4.85%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$1.58 +0.00 (+0.32%)

As of 10/16/2026 04:28 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Oramed Pharmaceuticals NASDAQ:ORMP

$4.07 -0.11 (-2.63%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$4.08 +0.01 (+0.25%)

As of 10/16/2026 07:30 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Whitehawk Therapeutics NASDAQ:WHWK

$2.89 -0.15 (-4.93%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$2.98 +0.09 (+2.94%)

As of 10/16/2026 04:35 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, WHWK, ADAG, and ORMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, WHWK, ADAG, and ORMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, WHWK, ADAG, and ORMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, WHWK, ADAG, and ORMP Company Descriptions

Adagene NASDAQ:ADAG

INmune Bio NASDAQ:INMB

Oramed Pharmaceuticals NASDAQ:ORMP

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMB, WHWK, ADAG, and ORMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMB, WHWK, ADAG, and ORMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMB, WHWK, ADAG, and ORMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, WHWK, ADAG, and ORMP Company Descriptions

Adagene NASDAQ:ADAG

INmune Bio NASDAQ:INMB

Oramed Pharmaceuticals NASDAQ:ORMP

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools